Background: Loss of retinoic acid receptor beta (RAR-␤) expression in the bronchial epithelium is considered a biomarker of preneoplasia. Retinoids can restore expression of this receptor and, presumably, halt the progression of carcinogenesis. This study was designed to investigate whether either of two retinoid-based regimens, 9-cis-retinoic acid (RA) or 13-cis-RA plus ␣-tocopherol (AT), could reverse RAR-␤ expression loss in former smokers after 3 months of treatment. Methods: Individuals (n = 226) who had smoked at least 20 pack-years and had ceased smoking for at least 12 months were randomly assigned to receive 3 months of daily oral 9-cis-RA (100 mg), 13-cis-RA (1 mg/kg) + AT (1200 IU), or placebo. Bronchoscopy and biopsy at six predetermined sites of the bronchial tree were performed before treatment and at 3 and 6 months thereafter. Specimens were evaluated for squamous metaplasia, dysplasia, and RAR-␤ expression. McNemar's test was used to test changes in RAR-␤ expression and squamous metaplasia within each treatment group, and a generalized estimating equations model was applied to model the treatment effect, adjusting for covariates. All statistical tests were two-sided. Results: A total of 177 assessable subjects completed at least 3 months of therapy and underwent at least the baseline and 3-month bronchoscopic evaluations with biopsies. RAR-␤ was detected in 69.7% of all baseline biopsy samples, and metaplasia was evident in 6.9% of all baseline samples from 240 subjects. Restoration of RAR-␤ expression (P = .03) and reduction of metaplasia (P = .01) were found in the 9-cis-RA group. After adjustment for years of smoking, packs/day smoked, and metaplasia, treatment with 9-cis-RA, but not with 13-cis-RA + AT, led to a statistically significant increase in RAR-␤ expression compared with placebo (P = .03). Conclusion: 9-cis-RA treatment can restore RAR-␤ expression in the bronchial epithelium of former smokers, raising the possibility that this retinoid has potential chemopreventive properties in former smokers. 
Lung cancer is the leading cause of cancer-related death in the United States (1), largely because most cases of lung cancer are diagnosed after the disease has metastasized and because current therapeutic approaches for advanced lung cancer have little effect on disease-related mortality. Surgical resection of the primary tumor results in long-term cure for only about 50% of patients with early-stage lung cancer; the remaining patients either experience disease recurrence or develop a second primary tumor in the aerodigestive tract (2) . Clearly, given these findings, new treatment approaches are needed to reduce lung cancer-related mortality.
In light of the ineffectiveness of current therapeutic strategies in treating clinically evident lung cancer, investigative research efforts have focused on lung cancer prevention. Because exposure to cigarette smoke confers the greatest risk for developing lung cancer, with approximately 90% of all lung cancers occurring among individuals who smoke, smoking cessation campaigns have been a major focus of preventive efforts. The relative risk of developing lung cancer declines in former smokers to approximately twice that of individuals who have never smoked by 20 years after smoking cessation; however, it remains elevated in these individuals indefinitely (3) . There are 45 million former smokers in the United States, and 50% of newly diagnosed lung cancers occur in former smokers (3) . These findings illustrate the importance of targeting former smokers for lung cancer prevention studies and the need to identify chemopreventive strategies that will further reduce lung cancer risk in former smokers.
The agents most frequently studied in preclinical and clinical lung cancer chemoprevention studies thus far are the retinoids, which are natural and synthetic compounds related to vitamin A (retinol) and retinoic acid (RA) (4) . Retinoids act by binding and transcriptionally activating nuclear retinoid receptors. Each of the two families of retinoid receptors, retinoic acid receptors (RARs) and retinoid X receptors (RXRs), has three members (␣, ␤, and ␥) (5) . These receptors function as RXR:RAR heterodimers and RXR:RXR homodimers. Of the naturally occurring retinoids, all-trans-RA binds to RARs, and 9-cis-RA binds to both RARs and RXRs. 13-cis-RA binds to neither receptor type and is thought to bind after stereoisomerization to either all-trans-RA or 9-cis-RA, a process that occurs intracellularly (6) . Because 9-cis-RA binds to both RARs and RXRs, it can activate RXR:RAR heterodimers, RXR:RXR homodimers, and other nuclear receptor complexes in which the RXR is a ligandbinding partner, such as the vitamin D receptor and the peroxisome proliferator-activated receptor (5) . Thus, because of its unique receptor-binding properties, 9-cis-RA has biologic effects that all-trans-RA and 13-cis-RA do not. Supporting this concept, single-agent 9-cis-RA was effective in the chemoprevention of mammary and prostate cancer in preclinical studies, and it enhanced the antitumor effects of cisplatin against human oral squamous carcinoma xenografts (7) (8) (9) . Furthermore, Targretin (Ligand Pharmaceuticals, San Diego, CA) a synthetic retinoid that binds selectively to RXRs, also demonstrated efficacy in preclinical models of mammary cancer chemoprevention, suggesting that RXR is an important target for the chemoprevention of epithelial cancer (10, 11) .
The retinoid that has demonstrated the greatest activity in the prevention of aerodigestive tract cancer is 13-cis-RA. In patients with a previous cancer of the head and neck region, high-dose 13-cis-RA treatment reduced the incidence of second primary tumors and decreased leukoplakia (i.e., premalignant oral lesions), which is evident on physical examination and microscopic evaluation of leukoplakia biopsies (12) . This latter effect correlated with the ability of 13-cis-RA to increase the expression of RAR-␤, a retinoic acid-responsive gene whose expression is lost in premalignant epithelial lesions of several organs, including those of the aerodigestive tract (13, 14) . This chemopreventive activity of 13-cis-RA against head and neck cancer will require confirmation by large-scale chemoprevention trials, which are currently ongoing.
Although effective in the prevention of head and neck cancer, retinoids have not yet been demonstrated to be active in the prevention of lung cancer. In fact, several large-scale trials, including the Beta-Carotene and Retinol Efficacy Trial (CARET), the Alpha-Tocopherol, Beta-Carotene (ATBC) Cancer Prevention Study, and the National Cancer Institute-sponsored Intergroup Lung Study, have demonstrated that retinoids may actually enhance lung cancer incidence in individuals who smoke (15) (16) (17) . In contrast, retinoid treatment reduced tumor recurrence and mortality in nonsmokers, and there was some evidence of benefit, albeit not statistically significant, in tumor recurrence and mortality in former smokers (17) , suggesting that current and former smokers differ in their response to retinoids. Supporting these findings, 13-cis-RA treatment of current smokers had no effect on bronchial squamous metaplasia, a histologic abnormality associated with smoking, whereas 13-cis-RA treatment conferred some evidence of reduction in bronchial squamous metaplasia in former smokers (18) . However, the number of former smokers enrolled in these studies was small, and additional investigations are needed to address whether former smokers may be a better target population than current smokers for retinoid-based chemoprevention studies.
On the basis of these findings, we sought to investigate the activity of 9-cis-RA in the reversal of bronchial premalignancy in former smokers and to compare it with the activity of 13-cis-RA in combination with ␣-tocopherol (AT), which has been shown to reduce the toxic effects of 13-cis-RA and to have intrinsic chemopreventive activity of its own (19, 20) . We focused on former smokers so that we could characterize the biology of the bronchial epithelium and its response to retinoids in the absence of continuous exposure to cigarette smoke carcinogens. Histologic evidence of bronchial premalignancy has been detected in only approximately 30% of former smokers (18) . Therefore, we chose as the primary endpoint of this study the reversal of RAR-␤ expression loss in the bronchial epithelium. We have found in preliminary studies that RAR-␤ expression loss, a biomarker of bronchial premalignancy, is found in approximately 60% of former smokers. We hypothesized that in former smokers, loss of expression of RAR-␤ is a marker of bronchial preneoplasia and that its restoration reflects suppression of bronchial preneoplasia.
SUBJECTS AND METHODS

Subjects
A three-arm, randomized, double-blinded, placebo-controlled trial was conducted to compare the effects of 9-cis-RA (100 mg) with those of 13-cis-RA (1 mg/kg) plus AT (1200 IU) on loss of RAR-␤ expression in bronchial epithelial biopsies from former smokers. For the purpose of this study, former smokers were defined as individuals who had a smoking history of at least 20 pack-years and who had stopped smoking at least 1 year before study entry. Subjects were identified through advertisements that were distributed to referring doctors and patients at The University of Texas M. D. Anderson Cancer Center, provided to local health fairs and community groups, and distributed through local and national media campaigns. To be eligible, subjects had to have adequate renal, hematologic, and hepatic function and must not have taken more than 25 000 IU of vitamin A or other retinoids per day within 3 months of study entry. Subjects were allowed to have had a prior smoking-related cancer, but they had to have been tumor-free for 6 months before enrollment in the study. Subjects were required to abstain from consuming vitamin A dietary supplements during treatment on the study. This study was approved by the Institutional Review Board at The University of Texas M. D. Anderson Cancer Center and by the U.S. Department of Health and Human Services. Prior to being randomly assigned, all eligible subjects provided written informed consent.
Trial Design
This trial originally began as a two-arm trial to compare the activity of 13-cis-RA + AT with that of placebo in former smokers using metaplasia index as the primary endpoint. The eligibility criteria for the original trial were the same as those for the subsequent one, except for a requirement for detectable bronchial squamous metaplasia (i.e., a metaplasia index of >15%, dysplasia, or both) at the time of the baseline screening bronchoscopy. The treatment duration was 6 months in the original trial rather than the 3-month treatment duration for the present trial. Under the original trial design, 13 subjects were registered between November 21, 1995, and September 4, 1996. However, 10 subjects could not be randomly assigned after their baseline screening bronchoscopy because of an inadequate metaplasia index (i.e., ഛ15%). After modification to the three-arm trial, a further 227 subjects were registered between February 1997 and May 2001, of whom 223 were eligible for random assignment. Of the four patients who were not randomly assigned, one had intercurrent illness, one had a complication from bronchoscopy and wished to drop out, one was ineligible because of high triglyceride levels, and one dropped out for personal reasons. Altogether, 240 subjects were registered in the trial, of whom 226 were randomly assigned to one of the treatment arms (Fig. 1 ).
In the baseline screening bronchoscopy, biopsy samples were obtained from six predetermined sites in the bronchial tree-the main carina, the bifurcation of the right upper lobe and mainstem bronchus, the bifurcation of the right middle lobe and right lower lobe, the bifurcation of the left upper lobe and the lingula, the medial bronchus of the right lower lobe, and the anterior bronchus of the left lower lobe. Subjects were seen monthly and evaluated for compliance with the trial protocol, drug-related toxic effects, and serum 13-cis-RA drug levels. Serum cotinine levels were drawn at baseline, 3 months, and 6 months to document compliance with smoking abstinence during the trial.
Because toxicity data from prior phase I trials that included 9-cis-RA treatment of cancer patients did not extend beyond 3 months of treatment (21, 22) , the duration of retinoid treatment for this study was 3 months. At that time, a second bronchoscopic examination with biopsy was performed to evaluate the bronchial tree for evidence of change. Drug-related toxicity was graded according to the National Cancer Institute's Common Toxicity Criteria (CTC, version 2.0; http://ctep.cancer.gov/ forms/CTCv20_4-30-992.pdf).
Treatment
Of the 226 eligible subjects, 75 were randomly assigned to the placebo group, 77 to the 13-cis-RA + AT group, and 74 to the 9-cis-RA group (Fig. 1) . Treatment for all three groups was divided into twice-daily doses. Subjects took oral 9-cis-RA (or the placebo for it) in the evening and 13-cis-RA + AT (or the placebos for them) in the morning. 13-cis-RA was supplied by Hoffmann-LaRoche Pharmaceuticals (Nutley, NJ), AT by the Henkel Corporation (La Grange, IL), and 9-cis-RA by Ligand Pharmaceuticals (San Diego, CA).
The trial also included a crossover design based on the results of the baseline and 3-month bronchoscopy examinations. If disease progression was evident (i.e., if development of bronchial dysplasia and/or the metaplasia index increased) the subject's trial arm code was unblinded and the subject's treatment group assignment was revealed. If the subject had been in the placebo group, he or she was crossed over to undergo 3 months of treatment with 13-cis-RA + AT. If the subject had been in the 13-cis-RA + AT group or the 9-cis-RA group, treatment was discontinued.
Biopsy Specimens
Specimens were fixed in buffered formalin, embedded in paraffin, and sliced into 4-m sections (23) . Ten sections per biopsy site were stained with hematoxylin-eosin and evaluated for the presence of dysplasia and squamous metaplasia by a pathologist (J. Y. Ro) blinded to the timing of specimen collection and the treatment group. Squamous metaplasia was quantified with a metaplasia index (23) , in which the number of biopsy sections from each subject exhibiting squamous metaplasia was divided by the total number of sections examined for that time point, and the result was multiplied by 100. The 15% cutoff point for the metaplasia index was established based on the fact that 10 sections were analyzed from each biopsy, with six sites per subject. Typically, if metaplasia was seen in a biopsy, then it was seen in all 10 sections. Thus, this amounts to 10/60 (16.6%) sites. In this situation, one biopsy site with complete squamous metaplasia would place a subject over the 15% cutoff point. However, if one biopsy site has only partial squamous metaplasia, then the subject would be classified as being below the 15% cutoff point. In addition to its analysis as a continuous variable, squamous metaplasia was analyzed on a per-site basis as a binary variable.
In Situ mRNA Hybridization Studies
RAR-␤ mRNA levels in tissue sections were analyzed by nonradioactive in situ hybridization (24) . Briefly, digoxygeninlabeled antisense RAR-␤ riboprobes were hybridized to 4-m sections of the formalin-fixed, paraffin-embedded biopsy specimens. Probe binding was visualized by incubating sections with peroxidase-conjugated antidigoxygenin antibodies followed by a peroxidase substrate. Specificity of binding was confirmed with digoxygenin-labeled sense probes. To control for RNA degradation, we used an antisense riboprobe for RXR-␣, a ubiquitous retinoid receptor. Expression of RAR-␤ was analyzed in one section in each of the assessable (i.e., containing sufficient epithelium for interpretation) biopsy sites for each subject (i.e., up CONSORT flow diagram for subjects who were former smokers accrued into the trial. Subjects were randomly assigned to receive daily oral 9-cis-RA (retinoic acid), 13-cis-RA + ␣-tocopherol (AT), or placebo. N C ‫ס‬ number of subjects completing 3 months or 6 months of treatment and who had a second and third bronchial biopsy. N R ‫ס‬ number of subjects with assessable retinoic acid receptor beta (RAR-␤) expression. * ‫ס‬ One of these subjects was incorrectly crossed over to the 13-cis-RA + AT arm. Therefore, only 59 subjects were assessable for metaplasia index and 58 were assessable for RAR-␤ expression.
to six sections per subject). RAR-␤ mRNA expression in the bronchial biopsy samples was quantified in terms of an RAR-␤ index, in which the number of biopsy sections from each subject expressing RAR-␤ mRNA was divided by the total number of sections examined, and the result was multiplied by 100. In addition to its analysis as a continuous variable, RAR-␤ was analyzed as a binary variable.
Statistical Analysis
Summary statistics, including frequency tabulation, means, standard deviations, median, and range, were given to characterize subject characteristics, expression of RAR-␤, and metaplasia index. The Wilcoxon rank sum test and Kruskal-Wallis test were used to test the equal median of continuous variables among two and three treatment groups, respectively. The chisquare ( 2 ) test or Fisher's exact test was used to test the association between two categorical variables. McNemar's test and Wilcoxon signed-rank test (25) were used to test changes in RAR-␤ expression and squamous metaplasia by subject over time within each treatment group. When the biopsy site was used as the unit of analysis (under the assumption that the site was nested within the subject), the generalized estimating equations model (26) was applied to model the treatment effect on RAR-␤ expression and squamous metaplasia, adjusting for covariates, such as packs smoked per day and number of years of smoking. Changes in RAR-␤ index within each group were considered a secondary outcome variable. Assuming a 25% difference in RAR-␤ expression change from baseline to 3 months between the placebo and treatment groups, the study was designed to accrue 60 assessable subjects per group (i.e., n ‫ס‬ 180) to achieve 78% power to detect a treatment effect. All statistical tests were two-sided, with a 5% type I error rate. Statistical analysis was performed with standard statistical software, including SAS Release 8.1 (SAS Institute, Cary, NC) and S-Plus 2000 (Mathsoft, Inc., Seattle, WA).
RESULTS
Subject Characteristics
Two hundred forty subjects were registered into the clinical trial, of whom 226 were eligible for being randomly assigned (Fig. 1) . As required under the original eligibility criteria (before the protocol was revised), 10 of the original 13 subjects were not included because of an inadequate metaplasia index at baseline bronchoscopy. Three other subjects of the next 227 were excluded because of intervening health problems after bronchoscopic examination, and one was excluded because of personal reasons. The three treatment groups (placebo, 13-cis-RA + AT, and 9-cis-RA) were well balanced for age, sex, race, history of smoking-related cancer, numbers of pack-years and quit-years of smoking, and metaplasia index (Table 1) . Twenty-two of the 226 subjects had had a prior smoking-related cancer, including 18 lung cancers, three head and neck cancers, and one bladder cancer. Of the 226 subjects, 46 withdrew from treatment before the 3-month time point-11 because of treatment-related toxic effects and 35 because of inconvenience (e.g., changes in job status or relocation out of the area). An additional three subjects were excluded because their second bronchoscopy was performed 6 months after rather than 3 months after treatment initiation. Thus, 177 subjects were assessable for response, on the basis of having completed at least 3 months of treatment and
Compliance With Protocol
Protocol eligibility required that subjects had stopped smoking at least 12 months before being randomly assigned. Serum cotinine levels drawn at registration, at 3 months, and at 6 months indicated that more than 95% of the participants had serum levels in the range of nonsmokers (<1.0 ng/mL) or passive smokers (1-20 ng/mL) at all three measurement times. Based on serum cotinine data, seven of the 226 randomly assigned subjects either resumed smoking or smoked continuously during their participation in the study. Exclusion of these subjects from the data analysis did not change the results of the study (data not shown); therefore, we have included these seven subjects in this report.
Among the 226 randomly assigned subjects, compliance with the treatment aspect of the protocol-determined as having taken at least 80% of the prescribed doses according to a review of subjects' monthly calendars and pill counts-varied with treatment group. Patients treated with 9-cis-RA were less compliant than patients in the other treatment groups, particularly in the third month of treatment (Table 2) . A chi-square test showed that compliance at the 3-month time point in the 9-cis-RA group (50%) was statistically significantly lower than in the placebo group (70%) (difference ‫ס‬ 20%, 95% confidence interval [CI] ‫ס‬ 5% to 38%; P ‫ס‬ .01) or the 13-cis-RA group (73%) (difference ‫ס‬ 23%, 95% CI ‫ס‬ 8% to 38%; P ‫ס‬ .004). The lower compliance among patients treated with 9-cis-RA may reflect the severe headaches reported by those receiving this drug. These headaches occurred early in the treatment regimen and typically did not improve with the use of nonsteroidal antiinflammatory agents.
We also monitored compliance by measuring serum 13-cis-RA levels at the baseline, 3-month, and 6-month visits. At the time of the 3-month bronchoscopy, all but six subjects in the 13-cis-RA group had detectable 13-cis-RA levels in their serum (these six subjects were included in the analysis). None of the subjects in the 9-cis-RA or placebo groups had detectable 13-cis-RA levels. Compliance with treatment with 9-cis-RA was not monitored, because we did not have an assay to detect for it.
Of the 177 subjects who were assessable for response, nine subjects in the 9-cis-RA group had evidence of disease progression (i.e., an increase in the metaplasia index, an increase in bronchial dysplasia, or both) at the 3-month time point. Nine subjects in the 13-cis-RA + AT group showed disease progression as manifested by an increase in the metaplasia index at the 3-month time point (one developed dysplasia), one of whom was mistakenly crossed over to the 13-cis-RA + AT group. Thirteen subjects in the placebo group had evidence of disease progression at the 3-month time point, 12 of whom crossed over to the 13-cis-RA + AT group, and one dropped out shortly after the 3-month time point.
Toxic Effects
Of the 226 randomly assigned subjects, 93 experienced grade 1 toxic effects, 89 experienced grade 2 toxic effects, 13 experienced grade 3 toxic effects, and none experienced grade 4 toxic effects or serious adverse events (grading was in accordance with the National Cancer Institute's Common Toxicity Criteria) ( Table 3) . Among the treatment groups, subjects in the 9-cis-RA group experienced the most grade 2 (46 subjects) and grade 3 (nine subjects) toxic effects. In general, the most common toxic effects were those typical of retinoid treatment, including skin rash, hypertriglyceridemia, headache, cheilitis, conjunctivitis, arthralgia, and myalgia. By protocol design, grade 2 or higher toxicity necessitated dose reductions of 50%. Treatment-related toxicity, therefore, necessitated dose reduction in 87 of 102 (85.3%) subjects (eight of nine subjects in the placebo group, 30 ‡All smoking-related cancers were lung cancers except for two head and neck cancers and one bladder cancer in the 13-cis-RA + AT group and one head and neck cancer in the 9-cis-RA group. §Metaplasia index ‫ס‬ the number of biopsy sections from each subject exhibiting squamous metaplasia divided by the total number of sections examined for that time point multiplied by 100. *RA ‫ס‬ retinoic acid; AT ‫ס‬ ␣-tocopherol. †The percentage of subjects who complied with the treatment protocol during each month of treatment. Compliance was defined as a subject's having taken at least 80% of the prescribed doses according to a review of the subjects' monthly calendars. Dropouts, missing compliance information, and drug withheld due to toxicity were considered noncompliance events. †One subject had grade 2 arthralgia, one had grade 3 arthralgia, and one had grade 2 photosensitivity.
‡One subject had grade 3 hypertriglyceridemia, one had grade 2 flu-like symptoms, four had grade 2 headaches, and two had grade 3 headaches. of 38 subjects in the 13-cis-RA + AT group, and 49 of 55 subjects in the 9-cis-RA group). For the remaining 15 subjects with grade 2 or higher toxicities, dose was not reduced because of symptom resolution (four), attrition from the study (three), or detection of the toxicity at the time of treatment completion (eight).
RAR-␤ Expression in the Bronchial Epithelium
The primary endpoint of this study was restoration of RAR-␤ expression in the bronchial epithelium. RAR-␤ mRNA was detected at baseline in 69.7% (948 of 1357) of the biopsy samples from the 240 registered subjects. Of the 174 subjects who were assessable for response based on having biopsy samples assessable for RAR-␤ expression at baseline and at the 3-month time point, 109 (62.6%) had loss of RAR-␤ expression at baseline in at least one of the six biopsy sites sampled. We examined the effects of treatment on RAR-␤ expression in two ways: as a continuous variable (i.e., RAR-␤ index) and as a binary variable (i.e., loss of RAR-␤ expression at any biopsy site). Although changes in RAR-␤ index from baseline to the 3-month time point did not reach statistical significance within treatment groups, compared with the effect of placebo, the median change in receptor index was statistically significantly different from placebo for 9-cis-RA (P ‫ס‬ .045) but not for 13-cis-RA + AT (P ‫ס‬ .41) ( Table 4) .
To determine the effect of treatment on loss of RAR-␤ expression at any biopsy site, we grouped subjects in terms of whether their biopsy samples were positive (i.e., RAR-␤ was detected in all six biopsy sites) or negative (i.e., RAR-␤ was not detected in at least one biopsy site) for RAR-␤ expression. We hypothesized that if a treatment was ineffective, the proportion of individuals who would convert from negative to positive over the 3-month treatment period would be equal to the proportion of individuals who would convert from positive to negative. This hypothesis held true for the placebo group, in which 14 subjects changed from negative to positive and 21 subjects changed from positive to negative (P ‫ס‬ .24), and the 13-cis-RA + AT group, in which 18 subjects changed from negative to positive and 13 subjects changed from positive to negative (P ‫ס‬ .37), but not for the 9-cis-RA group (P ‫ס‬ .03), in which 15 subjects changed from negative to positive and five changed from positive to negative (Table 4 ).
In the analysis by site, the increase in RAR-␤ expression in the 9-cis-RA group was statistically significantly different from that in the placebo group (odds ratio [OR] ‫ס‬ 1.72, 95% CI ‫ס‬ 1.05 to 2.78; P ‫ס‬ .03), after adjusting for smoking years, packs smoked per day, and the presence of squamous metaplasia (by the generalized estimating equations model, Table 5 ). Thus, 9-cis-RA was unique in its ability to increase RAR-␤ expression in the bronchial epithelium.
Squamous Metaplasia in the Bronchial Epithelium
Overall, squamous metaplasia was detected at baseline in 6.9% of biopsy sites (96 of 1399) and 29.6% of subjects (71 of 240), which included biopsy specimens from all registered participants. Of the 1007 pairs (i.e., baseline and 3-month) of biopsy samples examined from the 177 subjects who were assessable for response, squamous metaplasia was detected at baseline in 9.2% of the placebo group (32 of 348 sites), 5.8% of the 13-cis-RA + AT group (21 of 359 sites), and 8.0% of the 9-cis-RA group (24 of 300 sites). Evidence of dysplasia was noted in only five biopsy samples from five subjects. At the 3-month time point, the mean percentage of biopsy sites with squamous metaplasia had decreased to 7.8% in the placebo group (27 of 348 sites), 3.6% in the 13-cis-RA + AT group (13 of 359 sites), and 4.7% in the 9-cis-RA group (14 of 300 sites).
We also examined the effect of treatment on squamous meta- *RA ‫ס‬ retinoic acid; AT ‫ס‬ ␣-tocopherol. †RAR-␤ index ‫ס‬ the percentage of six biopsy sites in each subject that was positive; shown as mean ± standard error and median (range).
‡Modulation of RAR-␤ index was calculated as (RAR-␤ index at 3 months minus RAR-␤ index at baseline); shown as mean ± standard error and median (range).
§Wilcoxon rank-sum test was performed to test equal modulation of RAR-␤ index between placebo and 13-cis-RA + AT; P ‫ס‬ .41.
Wilcoxon rank-rum test was performed to test equal modulation of RAR-␤ index between placebo and 9-cis-RA; P ‫ס‬ .045.
¶Wilcoxon signed-rank test was performed to test the statistical significance of the change in the median RAR-␤ index modulation (3-month minus baseline) in each treatment group.
նSubjects were grouped according to RAR-␤ expression at baseline and at 3 months (+/+, +/−, −/+, −/−), "+" indicates that RAR-␤ was detected in all six biopsy sites; "−" indicates that RAR-␤ was not detected in at least one biopsy site. Number of subjects with each combination of RAR-␤ expression is given. **McNemar's test was performed to test the statistical significance of modulation of RAR-␤ expression relative to that in other treatment groups over time. plasia quantified as a continuous variable (metaplasia index) and as a binary variable (squamous metaplasia detected in at least one biopsy site). The mean metaplasia index declined from baseline to the 3-month time point in all three treatment groups (Table 6 ), but the declines were not statistically significant within treatment groups or when compared between treatment groups. The percentage of subjects with detectable squamous metaplasia declined in all three treatment groups, but this decline was statistically significant only in the 9-cis-RA group (P ‫ס‬ .01, Table 6 ). However, relative to the effect of placebo, the change in squamous metaplasia in the 9-cis-RA and 13-cis-RA + AT groups did not reach statistical significance (P ‫ס‬ .30 and P ‫ס‬ .42, respectively, by the generalized estimating equations model) (data not shown).
Of the 12 subjects who crossed over to the 13-cis-RA group, 11 were assessable for the 6-month response and one subject dropped out before the 6-month evaluation. Three subjects had an increase in RAR-␤ index and a decrease in metaplasia index, and eight subjects had no change or a decrease in RAR-␤ index, of which six had a decrease and two had an increase in metaplasia index. The number of participants who crossed over is too small to permit making a conclusion about the effect of treatment on this subgroup.
DISCUSSION
In this article, we present the first study, to our knowledge, in which people who have (according to self-report) quit smoking are the target population for the chemoprevention of bronchial premalignancy. From the perspective of directing future public health initiatives, the findings of our study are important, because we have shown both that clinical trials targeting former smokers are feasible and that 9-cis-RA can modulate a biomarker of bronchial preneoplasia-RAR-␤ expression-in this population. The finding that 9-cis-RA can modulate a bronchial preneoplasia biomarker differs from those of prior retinoidbased studies in current smokers (15) (16) (17) (18) , which have demonstrated no benefit from chemopreventive intervention with respect to either lung cancer risk or reversal of biomarkers of bronchial premalignancy. Thus, the efficacy of retinoids in the chemoprevention of bronchial premalignancy may differ in current and former smokers.
The primary endpoint of this study was restoration of RAR-␤ expression in the bronchial epithelium. We observed that subjects in the 9-cis-RA group, but not those in the 13-cis-RA group, had statistically significantly increased RAR-␤ expression compared with subjects in the placebo group. Several possible factors could have contributed to this unique activity of 9-cis-RA. First, unlike 13-cis-RA, which must be metabolized to all-trans-RA or 9-cis-RA before it can bind nuclear retinoid receptors (6), 9-cis-RA is a natural ligand for both RARs and RXRs. Thus, administration of 9-cis-RA may lead to higher levels of ligand available for receptor activation in the bronchial epithelium than can be achieved with administration of 13-cis-RA. Second, RAR-␤ expression is activated transcriptionally by retinoids through a response element in its gene promoter that binds to RAR:RXR heterodimers. Given the ability of 9-cis-RA to bind to both types of retinoid receptor (i.e., RAR and RXR), it can, therefore, activate both components of the heterodimeric complex, which could activate RAR-␤ gene transcription more potently than activation of either receptor alone (27) .
The inability of 13-cis-RA to increase RAR-␤ expression in the bronchial epithelium in this study differs from the findings of a previous report (28) . There are several possible explanations for this difference. First, the combination of 13-cis-RA with AT, as used in our study, could have influenced retinoid absorption, metabolism, or distribution. Second, the previous report (28) targeted current smokers. Evidence from our studies (29) demonstrates that the biology of the bronchial epithelium differs greatly between individuals who smoke and individuals who have stopped smoking. Cellular proliferation is higher among current smokers than it is among former smokers, and the characteristics of the proliferating bronchial epithelial cells differ with regard to their level of genomic instability (29) . These two factors could influence retinoid-induced levels of RAR-␤ in the bronchial epithelium.
Clearly, additional work will be necessary to determine whether the changes in RAR-␤ levels induced by 9-cis-RA correlate with their abilities to reduce lung cancer risk in former smokers. To begin to answer this question, we examined the effect of retinoid treatment on the level of bronchial squamous metaplasia in biopsy samples from the bronchial tree of former smokers. Comparing to placebo, neither 9-cis-RA nor 13-cis-RA + AT treatment had a statistically significant effect on squamous metaplasia in this study, but there was some evidence of benefit in reducing squamous metaplasia in the 9-cis-RA group. Under- *RA ‫ס‬ retinoic acid; AT ‫ס‬ ␣-tocopherol. †Metaplasia index is the percentage of six biopsy sites in each subject that was positive for squamous metaplasia; shown as mean ± standard error and median (range).
‡Modulation of the metaplasia index was calculated as (metaplasia index at 3 months minus metaplasia index at baseline); shown as mean ± standard error and median (range).
§Wilcoxon rank-sum test was performed to test equal modulation of metaplasia index between placebo and 13-cis-RA + AT; P ‫ס‬ .74.
Wilcoxon rank-sum test was performed to test equal modulation of metaplasia index between placebo and 9-cis-RA; P ‫ס‬ .68.
¶Wilcoxon signed-rank test was performed to test the median metaplasia index modulation in each treatment group.
նSubjects were grouped according to the presence or absence of squamous metaplasia at the baseline and 3-month time points (+/+, +/−, −/+, −/−). "+" indicated that squamous metaplasia was detected in at least one of six biopsy sites; "−" indicated that squamous metaplasia was not detected in any of the six biopsy sites. Number of subjects with each combination of squamous metaplasia is given. **McNemar's test was performed to test the statistical significance of modulation of squamous metaplasia relative to that in the other treatment groups over time.
standing the activity of 9-cis-RA in the reversal of bronchial premalignancy may require the design of a study that tests its effects in individuals who have histologic evidence of bronchial premalignancy. Alternatively, biomarkers of bronchial premalignancy may be required that are more prevalent in former smokers than squamous metaplasia, which we observed in only 29.6% of subjects. Such studies will require correlation of RAR-␤ expression with known biomarkers of bronchial epithelial premalignancy and novel biomarkers of premalignancy identified by proteomic and genomic analysis.
The toxic effects of 9-cis-RA and 13-cis-RA + AT observed in this study were similar in nature, frequency, and severity to those observed in a previous report of 13-cis-RA therapy (18) . In addition, headaches of similar nature and severity have also been observed in phase I studies of 9-cis-RA (21, 22) . The toxicities observed in this trial limit the usefulness of certain retinoids in chemoprevention strategies. For example, in patients with oral leukoplakia, 13-cis-RA treatment induces disease remission, but treatment cessation is associated with disease relapse (30) . Thus, chronic administration of retinoids may be necessary to suppress the progression of premalignant lesions of the aerodigestive tract. If so, it will be necessary to develop agents that are both effective and well tolerated in prolonged use.
Our finding that 9-cis-RA, a drug that activates both RARs and RXRs, was more effective at restoring RAR-␤ expression than a 13-cis-RA-based regimen suggests that agents that activate both RXRs and RARs may be more effective in reversing bronchial premalignancy than RAR-selective agents. An RXRselective agonist, LGD1069, has demonstrated activity against non-small-cell lung cancer in early clinical trials (31) .
LGD1069 is relatively well tolerated, has been administered for prolonged periods in responding patients and, when administered at high doses, has RAR-agonistic activity (32) . Based on our data, treatment with LGD1069 may augment expression of RAR-␤ and thereby reverse bronchial premalignancy. Thus, we suggest that drugs that activate both RARs and RXRs should be tested in biomarker-based lung cancer chemoprevention trials.
